Lu Zhao, Chen Haipeng, Zhang Mingguang, Guan Xu, Zhao Zhixun, Jiang Zheng, Liu Zheng, Zheng Zhaoxu, Wang Xishan
Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Chin J Cancer Res. 2020 Oct 31;32(5):654-664. doi: 10.21147/j.issn.1000-9604.2020.05.10.
The transanal approach to specimen collection, combined with the prolapsing technique, is a well-established and minimally invasive surgery for treating rectal cancer. However, reports on outcomes for this approach are sparse. We compared short- and long-term outcomes of conventional laparoscopic surgery (CLS) transanal natural orifice specimen extraction (NOSE) using the prolapsing technique for patients with middle- to low-rectal cancer.
From January 2013 to December 2017, we enrolled consecutive patients with middle- to low-rectal cancer undergoing laparoscopic anterior resection. Totally, 50 patients who underwent transanal NOSE using the prolapsing technique were matched with 50 patients who received CLS. Clinical parameters and survival outcomes between the two groups were compared.
Estimated blood loss (29.70±29.28 . 52.80±45.09 mL, P=0.003), time to first flatus (2.50±0.79 . 2.86±0.76, P=0.022), time to liquid diet (3.62±0.64 . 4.20±0.76 d, P<0.001), and the need for analgesics (22%. 48%, P=0.006) were significantly lower for the NOSE group compared to the CLS group. The incidences of overall complications and fecal incontinence were comparable in both groups. After a median follow-up of 44.52 months, the overall local recurrence rate (6% . 5%, P=0.670), 3-year disease-free survival (86.7% . 88.0%, P=0.945) and 3-year overall survival (95.6% . 96.0%, P=0.708), were not significantly different.
For total laparoscopic rectal resection, transanal NOSE using the prolapsing technique is effective and safe, and associated with less trauma and pain, a faster recovery, and similar survival outcomes compared to CLS.
经肛门标本采集联合脱垂技术是一种成熟的治疗直肠癌的微创手术。然而,关于该手术方式疗效的报道较少。我们比较了采用脱垂技术的经肛门自然腔道标本取出术(NOSE)与传统腹腔镜手术(CLS)治疗中低位直肠癌患者的短期和长期疗效。
2013年1月至2017年12月,我们纳入了连续接受腹腔镜前切除术的中低位直肠癌患者。总共50例行经肛门脱垂技术NOSE手术的患者与50例接受CLS手术的患者进行匹配。比较两组的临床参数和生存结局。
与CLS组相比,NOSE组的估计失血量(29.70±29.28对52.80±45.09 mL,P = 0.003)、首次排气时间(2.50±0.79对2.86±0.76,P = 0.022)、开始流食时间(3.62±0.64对4.20±0.76 d,P < 0.001)和镇痛需求(22%对48%,P = 0.006)显著更低。两组的总体并发症发生率和大便失禁发生率相当。中位随访44.52个月后,总体局部复发率(6%对5%,P = 0.670)、3年无病生存率(86.7%对88.0%,P = 0.945)和3年总生存率(95.6%对96.0%,P = 0.708)差异均无统计学意义。
对于全腹腔镜直肠癌切除术,采用脱垂技术的经肛门NOSE手术有效且安全,与CLS相比,创伤更小、疼痛更轻、恢复更快,生存结局相似。